ENLV Strangle Strategy
ENLV (Enlivex Therapeutics Ltd.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
ENLV (Enlivex Therapeutics Ltd.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $17.8M, a trailing P/E of 0.03, a beta of 1.49 versus the broader market, a 52-week range of 0.66-2.1, average daily share volume of 555K, a public-listing history dating back to 2014, approximately 71 full-time employees. These structural characteristics shape how ENLV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.49 indicates ENLV has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. The trailing P/E of 0.03 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a strangle on ENLV?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ENLV snapshot
As of May 15, 2026, spot at $0.72, ATM IV 25.70%, IV rank 3.48%, expected move 7.37%. The strangle on ENLV below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ENLV specifically: ENLV IV at 25.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a ENLV strangle, with a market-implied 1-standard-deviation move of approximately 7.37% (roughly $0.05 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ENLV expiries trade a higher absolute premium for lower per-day decay. Position sizing on ENLV should anchor to the underlying notional of $0.72 per share and to the trader's directional view on ENLV stock.
ENLV strangle setup
The ENLV strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ENLV near $0.72, the first option leg uses a $0.76 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ENLV chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ENLV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $0.76 | N/A |
| Buy 1 | Put | $0.68 | N/A |
ENLV strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ENLV strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ENLV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ENLV
Strangles on ENLV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ENLV chain.
ENLV thesis for this strangle
The market-implied 1-standard-deviation range for ENLV extends from approximately $0.67 on the downside to $0.77 on the upside. A ENLV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ENLV IV rank near 3.48% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ENLV at 25.70%. As a Healthcare name, ENLV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ENLV-specific events.
ENLV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ENLV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ENLV alongside the broader basket even when ENLV-specific fundamentals are unchanged. Always rebuild the position from current ENLV chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ENLV?
- A strangle on ENLV is the strangle strategy applied to ENLV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ENLV stock trading near $0.72, the strikes shown on this page are snapped to the nearest listed ENLV chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ENLV strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ENLV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 25.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ENLV strangle?
- The breakeven for the ENLV strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ENLV market-implied 1-standard-deviation expected move is approximately 7.37%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ENLV?
- Strangles on ENLV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ENLV chain.
- How does current ENLV implied volatility affect this strangle?
- ENLV ATM IV is at 25.70% with IV rank near 3.48%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.